Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis

Dermatitis. 2023 Dec 29. doi: 10.1089/derm.2023.0298. Online ahead of print.
No abstract available